Home Featured Page 183

Featured

Latest

Psilocybin for Cocaine Use Disorder: Peter Hendricks on a Trial Ten Years in the Making

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and What Comes Next; Pre-EO, DEA Poured Cold Water on Right to Try

God, Gabon, and Government: W. Bryan Hubbard on Ibogaine, the Executive Order, and What Comes Next

The Optimisation Problem: What Bryan Johnson’s 5-MeO-DMT Experiment Reveals About Psychedelics Going Mainstream

MindMed Collaborator Dr. Matthias Liechti to Present Topline Clinical Trial Results...

Numinus Wellness Inc. Reports Q2 2022 Results

Psychedelic Bulletin: Psychedelics X Big Pharma; $23m Round for At-Home Ketamine...

Psychedelic Research Bulletin: March 2022

MYND Life Sciences Announces $3.5 Million Share Offering

Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial...

COMPASS Pathways partners with One Mind to fund Rising Star Awards...

Mindset Pharma Strengthens IP Portfolio with Another New Provisional Patent Application...

Filament Health and Psyence Enter into Exclusive Licensing Agreement for Natural...

Psychedelic Bulletin: Numinus to Enter U.S. Clinics Market; Mydecine Announces Reverse...

EDITOR PICKS

Psilocybin for Cocaine Use Disorder: Peter Hendricks on a Trial Ten...

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.